Spruce Biosciences (NASDAQ:SPRB) Releases Quarterly Earnings Results

Spruce Biosciences (NASDAQ:SPRB) announced its quarterly earnings data on Tuesday. The company reported ($0.57) earnings per share (EPS) for the quarter, Zacks reports. Spruce Biosciences had a negative net margin of 555.23% and a negative return on equity of 62.10%.

Spruce Biosciences Price Performance

SPRB stock opened at $0.31 on Tuesday. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $12.99 million, a PE ratio of -0.33 and a beta of 2.39. Spruce Biosciences has a 52-week low of $0.24 and a 52-week high of $0.87. The stock’s 50 day moving average is $0.35 and its two-hundred day moving average is $0.42.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Spruce Biosciences in a research report on Monday, December 16th. Six analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $2.50.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.